FilingSEC EDGAR8-K
BridgeBio Oncology Therapeutics Announces New BBO-8520 Data and Strategic Prioritization
· SEC accepted
StagePhase 1
Filing content
The company announced positive clinical data for BBO-8520 and decided to prioritize resources on three key programs for KRAS-mutant cancers.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…